<DOC>
	<DOC>NCT00432679</DOC>
	<brief_summary>This study was designed to compare the efficacy and safety of BRL49653C versus placebo with concomitant use of sulfonyl urea (SU).</brief_summary>
	<brief_title>A Study Of BRL49653C For The Treatment Of Type 2 Diabetes (Combination Therapy With Sulfonyl Urea) -With Placebo Study</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>Inclusion criteria: Patients with type 2 diabetes mellitus managed by SU will be candidate for this study. These candidates will be checked up on their clinical laboratory data, and must have adequate blood, liver and kidney function. Exclusion criteria: Patient with serious cardiovascular disease or serious hepatic disease will not be eligible.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>rosiglitazone</keyword>
	<keyword>Avandia</keyword>
	<keyword>type 2 diabetes mellitus</keyword>
	<keyword>diabetes</keyword>
</DOC>